California Public Employees Retirement System Takes $19.15 Million Position in Roivant Sciences Ltd. $ROIV

California Public Employees Retirement System purchased a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 691,463 shares of the company’s stock, valued at approximately $19,154,000.

Other hedge funds have also added to or reduced their stakes in the company. Morgan Stanley lifted its position in Roivant Sciences by 31.7% during the 4th quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock valued at $1,266,402,000 after purchasing an additional 14,036,696 shares during the period. Vanguard Group Inc. grew its position in shares of Roivant Sciences by 8.4% during the 4th quarter. Vanguard Group Inc. now owns 42,059,041 shares of the company’s stock worth $912,681,000 after buying an additional 3,254,113 shares during the period. Rubric Capital Management LP grew its position in shares of Roivant Sciences by 14.7% during the 2nd quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company’s stock worth $229,574,000 after buying an additional 2,603,260 shares during the period. State Street Corp raised its stake in shares of Roivant Sciences by 4.8% during the second quarter. State Street Corp now owns 19,773,480 shares of the company’s stock worth $222,847,000 after buying an additional 911,827 shares during the last quarter. Finally, UBS Group AG raised its stake in shares of Roivant Sciences by 570.0% during the fourth quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock worth $399,080,000 after buying an additional 15,645,836 shares during the last quarter. Institutional investors own 64.76% of the company’s stock.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, Director Melissa B. Epperly sold 17,750 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $34.38, for a total value of $610,245.00. Following the completion of the sale, the director owned 16,474 shares of the company’s stock, valued at approximately $566,376.12. This represents a 51.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Eric Venker sold 200,000 shares of the stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $33.16, for a total transaction of $6,632,000.00. Following the completion of the sale, the chief executive officer owned 1,613,063 shares in the company, valued at approximately $53,489,169.08. This trade represents a 11.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 1,855,913 shares of company stock worth $62,649,633. 10.80% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Guggenheim raised their price objective on shares of Roivant Sciences from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, May 26th. Leerink Partners set a $42.00 target price on shares of Roivant Sciences in a research report on Thursday, May 21st. Weiss Ratings downgraded Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Piper Sandler restated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, May 21st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $34.00 price objective on shares of Roivant Sciences in a research note on Thursday, May 21st. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Roivant Sciences has an average rating of “Moderate Buy” and a consensus price target of $33.59.

Roivant Sciences Price Performance

Shares of NASDAQ:ROIV opened at $35.10 on Friday. The company has a market capitalization of $25.25 billion, a price-to-earnings ratio of -58.50 and a beta of 1.11. The firm’s 50 day simple moving average is $32.12 and its 200 day simple moving average is $28.58. Roivant Sciences Ltd. has a fifty-two week low of $10.90 and a fifty-two week high of $37.00.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.